Press release
Fallopian Tube Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)
Fallopian Tube Cancer Pipeline
Key Takeaways from the Fallopian Tube Cancer Pipeline Report
• DelveInsight's Fallopian Tube Cancer pipeline report depicts a robust space with 70+ active players working to develop 70+ pipeline therapies for Fallopian Tube Cancer treatment.
• The leading Fallopian Tube Cancer Companies working in the market include ImmunoGen, OncXerna Theraputics, Merck & Co, Alkermes plc, SOTIO a.s., Jiangsu HengRui Medicine, Advenchen Laboratories, LLC, OncoQuest, Medivation, Pfizer, Glycotope, Array Pharma, Astex Pharmaceuticals, Lee's Pharmaceutical, Genmab, Seagen, CSPC ZhongQi Pharmaceutical Technology, Zenith Epigenetics, AiVita Biomedical, Xencor Inc., Syndax Pharmaceuticals, ImmunoVaccine Technologies, Celsion, APIM Therapeutics, Regeneron Pharmaceuticals, Artios Pharma Ltd, Sumitomo Dainippon Pharma Oncology, Exelixis, Green3Bio, Inc., OncoMed Pharmaceuticals, Transgene, Tmunity Therapeutics, Genelux Corporation, OncoC4, Inc., CanariaBio Inc., Zentalis Pharmaceuticals, Artios Pharma, ImmunoGen, Inc., Shattuck Labs, Transgene, Sutro Biopharma, Mersana Therapeutics, Rhizen Pharmaceuticals, Atrecsa, Inc., and others.
• Promising Fallopian Tube Cancer Therapies in the various stages of development include Trabectedin, DOXIL, Dexamethasone, epothilone b, CP-547,632, Avastin, Docetaxel, and others.
• May 2024:- University of Colorado, Denver- A Phase II Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib in Recurrent Platinum Sensitive Ovarian, Peritoneal, and Fallopian Tube Cancer. The Principal Investigator hypothesizes the combination of MIRV and Olaparib is an effective, and tolerable, maintenance therapy strategy in platinum sensitive recurrent ovarian cancer.
• May 2024:- Imunon- Phase II Study Evaluating the Effect of IMNN-001 on Second Look Laparoscopy (SLL) in Combination With Bevacizumab (BEV) and Neoadjuvant Chemotherapy (NACT) in Newly Diagnosed With Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer. This is a 1:1 randomized, open label, multi-center phase I/II trial to evaluate the safety, dosing, efficacy, and biological activity of adding IMNN-001 to chemotherapy + BEV compared to chemotherapy + BEV alone.
• May 2024:- Bristol-Myers Squibb- A Phase 2 Open-label Randomized Study of Farletuzumab Ecteribulin (MORAb-202), a Folate Receptor Alpha-targeting Antibody-drug Conjugate, Versus Investigator's Choice Chemotherapy in Women With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. The purpose of the study is to assess the safety, tolerability, and efficacy of farletuzumab ecteribulin (MORAb-202) and compare it to Investigator's choice (IC) chemotherapy in female participants with platinum-resistant HGS ovarian, primary peritoneal, or fallopian tube cancer.
Request a sample and discover the recent advances in Fallopian Tube Cancer @ Fallopian Tube Cancer Pipeline Outlook Report- https://www.delveinsight.com/sample-request/fallopian-tube-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Fallopian Tube Cancer Overview
Fallopian Tube Cancer starts in the fallopian tubes, which connect a woman's ovaries to their uterus. Fallopian Tube Cancer is very rare. Only about 1% of all reproductive cancers in women start in the fallopian tubes. The causes and risk factors for developing primary Fallopian Tube Cancer are not known. In some cases, a woman may have a history of chronic infection and/or inflammation of the fallopian tubes (due to untreated sexually transmitted diseases, for example).
The Fallopian Tube Cancer treatment will take into account the patient's stage of the disease, medical history, current health and personal preference, and other factors. The goal of the treatment of Fallopian Tube Cancer is to get rid of the cancer completely with minimal side effects.
Fallopian Tube Cancer Emerging Drugs Profile
• Mirvetuximab Soravtansine: ImmunoGen
Mirvetuximab Soravtansine is an antibody drug conjugate designed to target folate receptor α (FRα). It consists of the humanized anti-FRα mAb M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4. It is currently in phase III stage of development and is being developed by Immunogen.
• Tisotumab vedotin: Genmab/Seagen
Tisotumab vedotin is designed to target tissue factor (TF) using our proprietary antibody-drug conjugate (ADC) technology. TF is highly expressed on many solid tumors, including ovarian, prostate, bladder, esophageal, endometrial, and lung tumors. Tisotumab vedotin is being developed in collaboration with Genmab. It is composed of Genmab's human monoclonal antibody (mAb) that binds to TF and Seagen's ADC technology that utilizes a cleavable linker and the cytotoxic drug monomethyl auristatin E (MMAE). It is currently in phase III stage of development.
• Pembrolizumab: Merck & Co.
Keytruda (pembrolizumab) is a drug developed by Merck used in cancer therapy. It is a monoclonal antibody, a protein that binds to specific ligands, which increases the ability of the immune system to help detect and fight tumor cells. Keytruda has already been approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain types of cancers including melanoma, non-small cell lung cancer, recurrent or metastatic head and neck cancer, classical Hodgkin lymphoma, and urothelial carcinoma. The drug is still under investigation for the treatment of ovarian cancer, Fallopian tube cancer and several other potential disease.
Learn more about Fallopian Tube Cancer in clinical trials @ Fallopian Tube Cancer Drugs- https://www.delveinsight.com/sample-request/fallopian-tube-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Fallopian Tube Cancer Therapeutics Assessment
There are approx. 70+ key Fallopian Tube Cancer companies which are developing the Fallopian Tube Cancer therapies. The companies which have their Fallopian Tube Cancer drug candidates in the most advanced stage, i.e. Phase III include, Immunogen.
DelveInsight's report covers around 70+ Fallopian Tube Cancer products under different phases of clinical development like
• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Discover more about Fallopian Tube Cancer in development @ Fallopian Tube Cancer Clinical Trials- https://www.delveinsight.com/sample-request/fallopian-tube-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Fallopian Tube Cancer Companies
ImmunoGen, OncXerna Theraputics, Merck & Co, Alkermes plc, SOTIO a.s., Jiangsu HengRui Medicine, Advenchen Laboratories, LLC, OncoQuest, Medivation, Pfizer, Glycotope, Array Pharma, Astex Pharmaceuticals, Lee's Pharmaceutical, Genmab, Seagen, CSPC ZhongQi Pharmaceutical Technology, Zenith Epigenetics, AiVita Biomedical, Xencor Inc., Syndax Pharmaceuticals, ImmunoVaccine Technologies, Celsion, APIM Therapeutics, Regeneron Pharmaceuticals, Artios Pharma Ltd, Sumitomo Dainippon Pharma Oncology, Exelixis, Green3Bio, Inc., OncoMed Pharmaceuticals, Transgene, Tmunity Therapeutics, Genelux Corporation, OncoC4, Inc., CanariaBio Inc., Zentalis Pharmaceuticals, Artios Pharma, ImmunoGen, Inc., Shattuck Labs, Transgene, Sutro Biopharma, Mersana Therapeutics, Rhizen Pharmaceuticals, Atrecsa, Inc., and others.
Fallopian Tube Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type
Fallopian Tube Cancer Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type
To know more about Fallopian Tube Cancer, visit @ Fallopian Tube Cancer Segmentation- https://www.delveinsight.com/sample-request/fallopian-tube-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Fallopian Tube Cancer Pipeline Report
• Coverage- Global
• Fallopian Tube Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Fallopian Tube Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Fallopian Tube Cancer Companies- ImmunoGen, OncXerna Theraputics, Merck & Co, Alkermes plc, SOTIO a.s., Jiangsu HengRui Medicine, Advenchen Laboratories, LLC, OncoQuest, Medivation, Pfizer, Glycotope, Array Pharma, Astex Pharmaceuticals, Lee's Pharmaceutical, Genmab, Seagen, CSPC ZhongQi Pharmaceutical Technology, Zenith Epigenetics, AiVita Biomedical, Xencor Inc., Syndax Pharmaceuticals, ImmunoVaccine Technologies, Celsion, APIM Therapeutics, Regeneron Pharmaceuticals, Artios Pharma Ltd, Sumitomo Dainippon Pharma Oncology, Exelixis, Green3Bio, Inc., OncoMed Pharmaceuticals, Transgene, Tmunity Therapeutics, Genelux Corporation, OncoC4, Inc., CanariaBio Inc., Zentalis Pharmaceuticals, Artios Pharma, ImmunoGen, Inc., Shattuck Labs, Transgene, Sutro Biopharma, Mersana Therapeutics, Rhizen Pharmaceuticals, Atrecsa, Inc., and others.
• Fallopian Tube Cancer Therapies- Trabectedin, DOXIL, Dexamethasone, epothilone b, CP-547,632, Avastin, Docetaxel, and others.
For further information on the Fallopian Tube Cancer Pipeline Therapeutics, reach out @ Fallopian Tube Cancer Products Development- https://www.delveinsight.com/sample-request/fallopian-tube-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Fallopian Tube Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Fallopian Tube Cancer - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Fallopian Tube Cancer Collaboration Deals
9. Late Stage Products (Phase III)
10. Mirvetuximab Soravtansine: ImmunoGen
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. Gimatecan: Lee's Pharmaceuticals
14. Drug profiles in the detailed report…..
15. Early stage products (Phase I)
16. TG4050: Transgene
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Fallopian Tube Cancer Key Companies
20. Fallopian Tube Cancer Key Products
21. Fallopian Tube Cancer- Unmet Needs
22. Fallopian Tube Cancer- Market Drivers and Barriers
23. Fallopian Tube Cancer- Future Perspectives and Conclusion
24. Fallopian Tube Cancer Analyst Views
25. Fallopian Tube Cancer Key Companies
26. Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Fallopian Tube Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated) here
News-ID: 3503382 • Views: …
More Releases from DelveInsight Business Research LLP
Alpha-1 Protease Inhibitor Deficiency Market Size 2032: CSL Behring, Grifols The …
DelveInsight's "Alpha-1 Protease Inhibitor Deficiency Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Alpha-1 Protease Inhibitor Deficiency, historical and forecasted epidemiology as well as the Alpha-1 Protease Inhibitor Deficiency market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Key Takeaways from the Alpha-1 Protease Inhibitor Deficiency Market Research Report
• The increase in Alpha-1 Protease Inhibitor Deficiency Market Size…
Amyloidosis Market Size Report 2032: Attralus Inc., Novotech Pty Limited, Criter …
DelveInsight's "Amyloidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Amyloidosis, historical and forecasted epidemiology as well as the Amyloidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Key Takeaways from the Amyloidosis Market Research Report
• The increase in Amyloidosis Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies…
Basal Cell Nevus Syndrome Market Size Report 2032: Latest FDA Approvals, Emergin …
DelveInsight's "Basal Cell Nevus Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Basal Cell Nevus Syndrome, historical and forecasted epidemiology as well as the Basal Cell Nevus Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Key Takeaways from the Basal Cell Nevus Syndrome Market Research Report
• The increase in Basal Cell Nevus Syndrome Market Size…
Biliary Atresia Market Size Report 2032: Latest FDA Approvlas and Pipeline Repor …
DelveInsight's "Biliary Atresia Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Biliary Atresia, historical and forecasted epidemiology as well as the Biliary Atresia market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Key Takeaways from the Biliary Atresia Market Research Report
• The increase in Biliary Atresia Market Size is a direct consequence of the increasing…
More Releases for Fallopian
Fallopian Tube Cancer Market Development, Trends, Segmentations Analysis
Global Fallopian Tube Cancer Market: Overview
The global market for fallopian tube cancer has been expanding alongside advancements in the domain of cancer research and development. The field of oncology has set on a spree of research advancements over the past decade. This trend is projected to result in development of improved cancer treatments and new avenues for seamless research. There have been several advancements in the field of women's…
Fallopian Tube Cancer Therapeutics Market Challenging Health Concerns 2028 | Pre …
Global Fallopian Tube Cancer Therapeutics Market: Overview
Fallopian tube cancer is a type of rare cancer that is only found in females. This type of cancer accounts for nearly 1 to 2 percent of all the gynecologic cancers. Since last several years, chemotherapy has been the only therapy available for the treatment of fallopian tube cancer. However, chemotherapy has several adverse side effects on health. Additionally, it also unable to offer…
Fallopian Tube Cancer Market report provide Exact forecast to 2027
The Fallopian Tube Cancer Market report offers a deep analysis of the Fallopian Tube Cancer trade. It demonstrates a quick outline of trade knowledge and key Information like Key Manufacturers , Types, Application, Table Of Content, etc of the market. The report highlights Top Venders from the worldwide and Fallopian Tube Cancer Market along with their worth of the Industry to see their progress. The worldwide Fallopian Tube Cancer analysis…
Fallopian Tube Cancer Market - Size, Share, Outlook, and Forecast till 2026
Fallopian Tubes also called as uterine tube are pair of tubes, which carry an egg from the ovary to the uterus. Fallopian tube cancer also called as tubal cancer is caused due to uncontrolled growth of cells in fallopian tubes that connect the ovaries and the uterus. This is very rare type of cancer and it is characterized by symptoms such as abnormal vaginal bleeding, especially after menopause, abdominal pain…
Fallopian Tube Cancer Market: Drivers, Regional Analysis, and Competitive Landsc …
Cells in the body divide and grow to replace damaged and old cells. Cell growth is highly regulated and when sufficient amount of cells are produced to replace the old ones, the division of normal cells is stopped. Regulation error in the cell division process can cause cells to continually divide in an uncontrollable manner, which leads to the development of tumor. Fallopian tubes are also known as oviducts, which…
Fallopian Tube Cancer Pharmaceutical and Healthcare Pipeline Review H2
Pune, India, 26th October 2017: WiseGuyReports announced addition of new report, titled “Fallopian Tube Cancer - Pipeline Review, H2 2017”.
Summary
Fallopian tube cancer is also called tubal cancer. It develops in the fallopian tubes, which serve as a connection between the ovaries and the uterus. It occurs very rarely. The common symptoms of fallopian tube cancer may include abnormal vaginal bleeding, especially after menopause, abdominal pain or a feeling of pressure…
